Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Has Average Price Target of $91.20 According to Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been given a consensus rating of “Moderate Buy” by the thirteen research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $91.20.

HALO has been the subject of several recent analyst reports. Citizens Jmp lifted their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, TD Cowen boosted their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, August 7th.

Halozyme Therapeutics Stock Performance

HALO opened at $109.86 on Wednesday. The stock has a market capitalization of $12.47 billion, a PE ratio of 32.79, a P/E/G ratio of 0.42 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics has a one year low of $61.22 and a one year high of $116.85. The business’s 50 day moving average price is $103.50 and its 200 day moving average price is $81.57.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same period last year, the company earned $1.54 EPS. The company’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts expect that Halozyme Therapeutics will post 8.25 EPS for the current year.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $107.24, for a total value of $2,144,800.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at $82,336,727.20. The trade was a 2.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 87,775 shares of company stock worth $9,311,844 in the last 90 days. Company insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of large investors have recently bought and sold shares of HALO. Cim Investment Management Inc. increased its stake in shares of Halozyme Therapeutics by 7.4% during the second quarter. Cim Investment Management Inc. now owns 9,121 shares of the biopharmaceutical company’s stock worth $714,000 after acquiring an additional 629 shares during the period. QRG Capital Management Inc. increased its position in Halozyme Therapeutics by 11.1% during the 2nd quarter. QRG Capital Management Inc. now owns 6,626 shares of the biopharmaceutical company’s stock worth $519,000 after purchasing an additional 662 shares during the period. Talon Private Wealth LLC acquired a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $839,000. Sequoia Financial Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $359,000. Finally, Tidal Investments LLC lifted its holdings in shares of Halozyme Therapeutics by 13.5% in the 2nd quarter. Tidal Investments LLC now owns 190,305 shares of the biopharmaceutical company’s stock valued at $14,895,000 after buying an additional 22,707 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.